Browsing by Author Burlone, ME

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)
19-Mar-2015Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinomaSmirne, C; Grossi, G; Pinato, DJ; Burlone, ME; Mauri, FA, et al
1-Jul-2019Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinomaHowell, J; Atkinson, SR; Pinato, DJ; Knapp, S; Ward, C, et al
14-Feb-2017Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.Howell, J; Pinato, DJ; Ramaswami, R; Arizumi, T; Ferrari, C, et al
2-Mar-2017On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective studyHowell, J; Pinato, DJ; Ramaswami, R; Bettinger, D; Arizumi, T, et al
1-Jul-2019Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysisBettinger, D; Pinato, DJ; Schultheiss, M; Sharma, R; Rimassa, L, et al
Feb-2017The ALBI grade provides objective hepatic reserve phenotyping across each BCLC stage of hepatocellular carcinomaPinato, DJ; Sharma, R; Yen, C; Arizumi, T; Kubota, K, et al
24-Jan-2017The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug developmentPinato, DJ; Yen, C; Bettinger, D; Ramaswami, R; Arizumi, T, et al
1-Jan-2017Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational studyYen, C; Sharma, R; Rimassa, L; Arizumi, T; Bettinger, D, et al